Skip to content
AnalystLens

Merck Quarterly Report for Q3 Ended Sep 30, 2024

Filing Date
Filed November 6, 2024
Period End
September 30, 2024
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 10-Q filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported solid financial results for the third quarter and the first nine months of 2024.

Total sales increased by 4% year-over-year to $16.7 billiona in the third quarter and by 7% to $48.5 billion for the nine-month period. This growth was primarily driven by strong performance in the oncology franchise, notably Keytruda, and contributions from the cardiovascular and animal health segments. Despite overall sales growth, the company faced some headwinds, including a decline in vaccine sales, particularly Gardasil/Gardasil 9 due to lower demand in China.

Additionally, sales of key diabetes medications like Januvia and Janumet continued to decline due to loss of exclusivity and pricing pressures. Research and Development expenses saw a significant increase, largely due to substantial charges from recent acquisitions, including EyeBio and MK-1045, impacting reported profitability. However, non-GAAP income remained strong, reflecting operational performance excluding these acquisition-related costs.

Key Highlights

  1. Total sales grew 4% to $16.7 billion in Q3 2024 and 7% to $48.5 billion in the first nine months of 2024, excluding foreign exchange impacts.
  2. Keytruda demonstrated robust growth, with sales up 17% in Q3 and 18% year-to-date, driven by new indications and broader market uptake.
  3. Significant R&D expenses were incurred due to acquisitions, notably EyeBio ($1.35B charge) and MK-1045 ($750M charge), impacting reported net income.
  4. Gardasil/Gardasil 9 sales declined 11% in Q3, primarily due to reduced demand in China from inventory issues with their partner, Zhifei.
  5. Januvia/Janumet sales continued their downward trend, declining 42% in Q3, due to loss of exclusivity, pricing pressures, and government rebate cap changes.
  6. The Animal Health segment showed positive growth, with sales up 6% in Q3, boosted by new product launches and the acquisition of Elanco's aqua business.
  7. Merck announced a new restructuring program (2024 Restructuring Program) expected to cost approximately $4.0 billion over several years to optimize manufacturing networks.

Financial Statements

Q3 FY2024 against Q3 FY2023

Line itemQ3 FY2024Q3 FY2023Change
Revenue$16.66B$15.96B+4.4%
Cost of Revenue$4.08B$4.26B−4.3%
Gross Profit$12.58B$11.70B+7.5%
R&D Expenses$5.86B$3.31B+77.3%
SG&A Expenses$2.73B$2.52B+8.4%
Net Income$3.16B$4.75B−33.5%
EPS (Basic)$1.25$1.87−33.2%
EPS (Diluted)$1.24$1.86−33.3%
Shares Outstanding (Basic)2.53B2.54B−0.1%
Shares Outstanding (Diluted)2.54B2.55B−0.2%

Frequently Asked Questions

  1. What was the primary driver of Merck's sales growth in Q3 2024?

    The primary driver of Merck's sales growth in the third quarter of 2024 was the strong performance of its oncology franchise, particularly Keytruda, which saw a 17% increase in sales. Growth was also supported by new product launches in the cardiovascular franchise (Winrevair) and increased sales in the animal health segment.

  2. Why did Merck's R&D expenses increase significantly in Q3 2024?

    Research and Development expenses increased significantly in the third quarter of 2024 due primarily to substantial charges related to recent business development transactions. These included charges of $1.35 billion for the acquisition of EyeBio and $100 million for a related milestone, as well as $750 million for the acquisition of MK-1045. These acquisition-related costs heavily impacted reported R&D expenses.

  3. What is impacting the sales of Gardasil/Gardasil 9?

    Sales of Gardasil/Gardasil 9 declined in Q3 2024, primarily driven by lower demand in China. This was due to a significant decline in shipments from their distribution partner, Zhifei, to public health institutions, resulting in elevated inventory levels. Merck expects this trend to continue impacting sales in China into 2025.

  4. What is the outlook for Januvia and Janumet sales?

    Sales of Januvia and Janumet continue to decline significantly, with a 42% drop in Q3 2024. This is attributed to loss of market exclusivity in major regions, increased pricing pressure, competitive landscape, and changes in US Medicaid rebate policies. While patent protection extends to May 2026 in the US for certain forms, significant volume and pricing declines are anticipated to continue.